NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

Within the open-label basket trial, patients with two copies of one of two high-risk APOL1 gene variants will receive MZE829.

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

The AI-driven tools are getting better at recommending biomarker-targeted therapies, but experts warn they aren't ready for prime time.

Moncyte Health's test evaluates biological differences in how cholesterol is transported and processed in cells, which can ...

The company has already kicked off an open-label Phase I trial of ABX1100 in Canada following positive results from a study of healthy volunteers.

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

The company is still seeking strategic options for its development programs, including nana-val, which it was testing in EBV-positive refractory lymphoma.

The FDA, which has stopped short of requiring DPYD testing for patients before receiving fluoropyrimidines, emphasized the ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...